Madden Securities’s Moderna MRNA Stock Holding History

Madden Securities’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-570	Closed	-$102K	–	252
2022 Q4	$102K	Buy	+570	New	+$93.2K	0.05%	130
2021 Q4	–	Sell	-2,621	Closed	-$1.01M	–	118
2021 Q3	$1.01M	Buy	+2,621	New	+$967K	0.55%	55

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Madden Securities's MRNA Position: Q1 2023 in Review

Madden Securities sold out of Moderna (MRNA) in Q1 2023, closing a stake of 570 shares — an estimated $102K sold.

Madden Securities first reported a position in MRNA in Q3 2021 and held it in 2 quarters. The position peaked at $1.01M in Q3 2021. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

Madden Securities reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
Madden Securities sold 570 Moderna shares in Q1 2023, an estimated $102K.
Madden Securities first reported a position in Moderna in Q3 2021 and held it in 2 quarters.
Madden Securities's Moderna position peaked at $1.01M in Q3 2021.
1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Madden Securities's 13F filing for Q1 2023, filed 21 Apr 2023.